Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:February 2000
End Date:March 2020

Use our guide to learn which trials are right for you!

A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel,
use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal
antibodies such as trastuzumab can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells. It is not yet known whether
combination chemotherapy plus trastuzumab is more effective than combination chemotherapy
alone for treating breast cancer.

PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy
together with trastuzumab works compared to combination chemotherapy alone in treating women
with node-positive stage II or stage IIIA breast cancer that overexpresses HER2.

OBJECTIVES:

- Compare the cardiotoxicity of doxorubicin and cyclophosphamide followed by paclitaxel
with or without trastuzumab (Herceptin®) in women with operable, node-positive breast
cancer that overexpresses HER2.

- Compare the effect of these regimens on disease-free and overall survival of these
patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number
of positive nodes (1-3 vs 4-9 vs 10 or more), administration of hormonal therapy (tamoxifen
vs anastrozole vs neither), surgery/radiotherapy (lumpectomy plus breast irradiation vs
lumpectomy plus breast irradiation plus regional irradiation vs mastectomy without
radiotherapy vs mastectomy with radiotherapy), paclitaxel schedule (every 3 weeks vs weekly),
and participating center. Patients are randomized to one of two treatment arms.

- Arm 1: Patients receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1.
Treatment repeats every 21 days for 4 courses. Approximately 3 weeks after the last
course, patients receive paclitaxel IV over 3 hours every 21 days for 4 courses OR
paclitaxel IV over 1 hour once weekly for 12 weeks (12 doses).

- Arm 2: Patients receive chemotherapy as in arm I and trastuzumab (Herceptin®) IV over 90
minutes on day 1 of the first course of paclitaxel. Trastuzumab is then administered IV
over 30 minutes weekly for 51 weeks, beginning on day 8.

All patients with estrogen or progesterone receptor-positive tumors receive hormonal therapy*
for at least 5 years, beginning within 3-12 weeks after the last dose of chemotherapy.
Patients who have received prior tamoxifen for prevention may be treated with additional
tamoxifen for no more than 5 years at the discretion of the principal investigator (PI).

NOTE: *Other hormonal therapeutic agents are allowed in sequence with or as an alternative to
tamoxifen therapy.

All patients previously treated with lumpectomy undergo breast irradiation beginning after
completion of chemotherapy and concurrently with trastuzumab (in arm 2) administration.
Patients previously treated with mastectomy may also receive radiotherapy. Radiotherapy is
administered daily for 5-6 weeks.

Patients are followed every 6 months for 5 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 2,700 patients will be accrued for this study within 4.75
years.

Inclusion criteria

- The patient must have a life expectancy of at least 10 years, excluding her diagnosis
of breast cancer. (Comorbid conditions should be taken into consideration, but not the
diagnosis of breast cancer.)

- The interval between the last surgery for breast cancer treatment (lumpectomy,
mastectomy, axillary dissection, or re-excision of lumpectomy margins) and
randomization must be less than or equal to 84 days.

- All of the following staging criteria must be met:

- Primary tumor must be T1-3 by clinical and pathologic evaluation.

- Ipsilateral nodes must be cN0-1 by clinical evaluation.

- Ipsilateral nodes must be pN1, pN2a, or pN3a by pathologic evaluation.

- M0

- Patients must have undergone either a total mastectomy and an axillary dissection or a
lumpectomy and an axillary dissection. Sentinel node biopsy is permitted, but must be
followed by an axillary dissection.

- The tumor must be invasive adenocarcinoma on histologic examination.

- The tumor must be determined to be HER2-positive prior to randomization. Assays
performed using fluorescent in situ hybridization (FISH) require gene amplification to
be eligible. Assays using immunohistochemistry (IHC) must be performed at an
NSABP-approved reference laboratory and require a strongly positive staining score.

- Patients must have an analysis of both estrogen and progesterone receptors performed
on the primary tumor prior to randomization. "Marginal," "borderline," etc., results
(i.e., those not definitely negative) will also be considered positive regardless of
the methodology used.

- At the time of randomization, the patient must have had the following: history and
physical exam, EKG, and PA and lateral chest x-ray within the past 3 months; and a
bilateral mammogram (or unilateral if patient has had a mastectomy) and a pelvic exam
(for women who have a uterus and who will be taking tamoxifen) within the past year.

- Within 3 months prior to entry, the patient must have a baseline left ventricular
ejection fraction (LVEF) measured by MUGA scan equal to or greater than the lower
limit of normal for the radiology facility. (If LVEF is > 75%, the investigator should
consider having the LVEF determination reviewed prior to randomization. Following
randomization, the LVEF determination may be reviewed up until the time of the post-AC
MUGA. Please note that if a more accurate value is obtained from the review of the
baseline MUGA, the corrected value must be submitted to the NSABP Biostatistical
Center before the post-AC MUGA is performed.)

- At the time of randomization:

- The postoperative absolute neutrophil count (ANC) must be ≥ 1500/mm3 (or
<1500/mm3 if, in the opinion of the investigator, this represents an ethnic or
racial variation of normal).

- Postoperative platelet count must be ≥ 100,000/mm3. Significant underlying
hematologic disorders must be excluded when the platelet count is above the upper
limit of normal for the lab.

- There must be postoperative evidence of adequate hepatic function, i.e., total
bilirubin must be ≤ ULN for the lab unless the patient has a chronic grade 1 bilirubin
elevation (>ULN to ≤1.5 x ULN) due to Gilbert's disease or similar syndrome; and
alkaline phosphatase must be <2.5 times the ULN for the lab; and the serum
glutamic-oxaloacetic transaminase (SGOT [AST]) must be <1.5 times the ULN for the lab.

- There must be postoperative evidence of adequate renal function (serum creatinine
within or less than the institution's normal range).

- Patients must have no clinical or radiologic evidence of metastatic disease.
Suspicious findings must be confirmed as benign by radiologic evaluation or biopsy. A
patient with skeletal pain is eligible for inclusion in the study if bone scan and/or
roentgenological examination fails to disclose metastatic disease.

- Patients with a history of non-breast malignancies are eligible if they have been
disease-free for 5 or more years prior to randomization and are deemed by their
physician to be at low risk for recurrence. Patients with the following cancers are
eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the
cervix, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.

- Prior to randomization, the investigator must designate whether the patients who had a
lumpectomy will receive local or locoregional radiation therapy. For patients who had
a mastectomy, the investigator must designate whether or not the patient will receive
radiation therapy. (Pre-randomization discussion and/or consultation with a radiation
oncologist is encouraged.) Note: Irradiation of any internal mammary nodes is
prohibited in this trial.

- Special conditions for eligibility of lumpectomy patients: irradiation and surgery

- Patients treated by lumpectomy and axillary node dissection to be followed by breast
radiation therapy must meet all the eligibility criteria in addition to the following:
Generally, lumpectomy should be reserved for tumors <5 cm. However, at the
investigator's discretion, patients treated with lumpectomy for tumors ≥ 5 cm are
eligible. The margins of the resected specimen must be histologically free of invasive
tumor and DCIS as determined by the local pathologist. In patients in whom pathologic
examination demonstrates tumor present at the line of resection, additional operative
procedures may be performed to obtain clear margins. This is permissible even if
axillary dissection has been performed. Patients in whom tumor is still present at the
resected margin after re-excision(s) must undergo total mastectomy to be eligible.
Whole breast irradiation is required. Irradiation of regional lymph nodes is optional,
but partial breast irradiation and irradiation of any internal mammary nodes are
prohibited in this trial. Intent to irradiate the axilla or other regional node groups
must be declared by the investigator prior to randomization for stratification
purposes.

- Special conditions for eligibility of mastectomy patients: irradiation. The decision
to use locoregional irradiation in patients who have undergone total mastectomy and
axillary node dissection must be declared by the investigator prior to randomization
for stratification purposes. Failure to adhere to the radiation therapy plan will be a
protocol violation.

Exclusion criteria

- Bilateral malignancy or a mass or mammographic abnormality in the opposite breast
suspicious for malignancy unless there is biopsy proof that the mass is not malignant.

- Primary tumor staged as T4 for any reason.

- Nodes staged as clinical N2 or N3 for any reason and nodes staged as pathologic pN2b,
pN3b, or pN3c.

- Prior history of breast cancer, including DCIS (patients with a history of lobular
carcinoma in situ [LCIS] are eligible).

- Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal
therapy administered for the currently diagnosed breast cancer prior to randomization.
The only exception is hormonal therapy, which may have been given for up to a total of
28 days anytime after diagnosis and before randomization. In such a case, hormonal
therapy must stop at or before randomization and be re-started if indicated following
chemotherapy.

- Prior anthracycline or taxane therapy for any malignancy.

- Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement
therapy, etc. (These patients are eligible only if this therapy is discontinued prior
to randomization.)

- Therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, or other
selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention.
(Patients are eligible only if these medications are discontinued prior to
randomization. These medications are not permitted while on the study except for the
use of tamoxifen as described in the protocol)

- Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
preclude a patient from being subjected to any of the treatment options or would
prevent prolonged follow-up.

- Cardiac disease that would preclude the use of Adriamycin, Taxol or Herceptin. This
includes:

- Active cardiac disease:

- angina pectoris that requires the use of antianginal medication;

- cardiac arrhythmia requiring medication;

- severe conduction abnormality;

- clinically significant valvular disease;

- cardiomegaly on chest x-ray;

- ventricular hypertrophy on EKG; or

- patients with poorly controlled hypertension, i.e., diastolic greater than 100
mm/Hg. (Patients with hypertension who are well controlled on medication are
eligible for entry.)

- History of cardiac disease:

- myocardial infarction documented as a clinical diagnosis or by EKG or any other
tests;

- documented congestive heart failure; or

- documented cardiomyopathy.

- Psychiatric or addictive disorders that would preclude obtaining informed consent.

- Pregnancy or lactation at the time of proposed randomization. This protocol excludes
pregnant or lactating women based on the fetal toxicity of both tamoxifen and Taxol
which are listed as Pregnancy Category D agents. Pregnant women who received tamoxifen
have experienced fetal deaths, birth defects, spontaneous abortions, and vaginal
bleeding. Women of reproductive potential must agree to use an effective barrier
method of contraception. Hormonal birth control methods are not permitted.

- Sensory/motor neuropathy ≥ grade 2, as defined by the NCI's Common Toxicity Criteria
version 2.0.

- Contraindications to corticosteroid use which, in the opinion of the investigator,
would preclude participation in this study.

- Concurrent treatment with other investigational agents.

- Sensitivity to benzyl alcohol.

- Special conditions for ineligibility of lumpectomy patients: irradiation and surgery.
For patients treated by lumpectomy with axillary dissection, breast irradiation is
required. Please see guidelines for radiation therapy in Appendix A. In addition, the
following patients will also be ineligible:

- Patients with diffuse tumors (as demonstrated on mammography) that would not be
considered surgically amenable to lumpectomy.

- Patients treated with lumpectomy in whom there is another clinically dominant
mass or mammographically suspicious abnormality within the ipsilateral breast
remnant. Such a mass must be biopsied and demonstrated to be histologically
benign prior to randomization or, if malignant, must be surgically removed with
clear margins.

- Patients in whom the margins of the resected specimen are involved with invasive
tumor or ductal carcinoma in situ (DCIS). Additional surgical resections to
obtain free margins are allowed. Patients in whom tumor is still present after
the additional resection(s) must undergo mastectomy to be eligible.
We found this trial at
142
sites
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
115 Business loop 70 w
Columbia, Missouri 65203
(573) 882-2100
Ellis Fischel Cancer Center at University of Missouri - Columbia At Ellis Fischel Cancer Center,...
?
mi
from
Columbia, MO
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
(972) 566-7000
Medical City Dallas Hospital If you have concerns for your health, that of a family...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
33 Villa Road, Suite 400
Greenville, South Carolina 29615
(864) 404-2045
CCOP - Greenville Cancer care in the last decade has made many advances. Most of...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
85 Retreat Ave # 2
Hartford, Connecticut 06102
?
mi
from
Hartford, CT
Click here to add this to my saved trials
701 Ilalo Street Suite 600
Honolulu, Hawaii 96813
808-586-3010
Cancer Research Center of Hawaii The University of Hawaii Cancer Center is the only National...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
200 Hawkins Drive
Iowa City, Iowa 52242
800-237-1225
Holden Comprehensive Cancer Center at University of Iowa Holden Comprehensive Cancer Center is dedicated to...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
11234 Anderson Street
Loma Linda, California 92354
(909) 558-4126
Loma Linda University Cancer Institute at Loma Linda University Medical Center Loma Linda University Cancer...
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
4300 Alton Road
Miami Beach, Florida 33140
(305) 674-2625
CCOP - Mount Sinai Medical Center The Mount Sinai Community Clinical Oncology Program (MSCCOP) is...
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
1400 South Orange Avenue
Orlando, Florida 32806
(407) 648-3800
M.D. Anderson Cancer Center at Orlando For more than twenty years, our cancer center has...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Diego, CA 92120Bus: -
San Diego, California 92120
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
?
mi
from
Albany, GA
Click here to add this to my saved trials
?
mi
from
Albany, NY
Click here to add this to my saved trials
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
5301 East Huron River Drive
Ann Arbor, Michigan 48106
1.877.590.5995
CCOP - Michigan Cancer Research Consortium The Community Clinical Oncology Program (CCOP) is a comprehensive...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1120 15th Street, BAA-5407
Augusta, Georgia 30912
(706) 721-2505
MBCCOP - Medical College of Georgia Cancer Center The Georgia Regents University (GRU) is located...
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Bangor, ME
Click here to add this to my saved trials
Bethesda, Maryland 20889
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Billings, Montana 59101
?
mi
from
Billings, MT
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Burlington, North Carolina 27216
?
mi
from
Burlington, NC
Click here to add this to my saved trials
?
mi
from
Burlington, VT
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
101 Manning Drive
Chapel Hill, North Carolina 27514
(919) 966-0000
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill One of the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Charleston, WV
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
(312) 864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45236
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45267
513-584-7698
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clearwater, Florida 33756
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1335 Dublin Road, Suite 124A
Columbus, Ohio 43215
(614) 488-2118
CCOP - Columbus As one of the original 20 CCOPs, the Columbus Community Clinical Oncology...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
?
mi
from
Davenport, IA
Click here to add this to my saved trials
Daytona Beach, Florida 32114
?
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Decatur, Illinois 62526
?
mi
from
Decatur, IL
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
300 East Locust St., Ste 350
Des Moines, Iowa 50309
(515) 244-7586
CCOP - Iowa Oncology Research Association The Iowa Oncology Research Association (IORA) was established by...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
400 E Third Street
Duluth, Minnesota 55805
(218) 786-3868
CCOP - Duluth The Duluth CCOP, established and funded by the National Cancer Institute (NCI)...
?
mi
from
Duluth, MN
Click here to add this to my saved trials
East Lansing, Michigan 48824
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
?
mi
from
Farmington, CT
Click here to add this to my saved trials
Fort Gordon, Georgia 30905
?
mi
from
Fort Gordon, GA
Click here to add this to my saved trials
100 Park Street
Glens Falls, New York 12801
518.926.1000
Charles R. Wood Cancer Center at Glens Falls Hospital Glens Falls Hospital is the largest...
?
mi
from
Glens Falls, NY
Click here to add this to my saved trials
100 Michigan Street, NE, MC012
Grand Rapids, Michigan 49503
(616) 391-1230
CCOP - Grand Rapids The Grand Rapids Clinical Oncology Program (GRCOP) is a community cancer...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Green Bay, Wisconsin 54301
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
?
mi
from
Greenbrae, CA
Click here to add this to my saved trials
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Huntsville, Alabama 35801
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
800 Prudential Drive
Jacksonville, Florida 32207
904.202.2000
Baptist Cancer Institute - Jacksonville For more than 20 years, health care consumers have named...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kalamazoo, Michigan 49007
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Kansas City, Missouri 64131
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kettering, Ohio 45429
?
mi
from
Kettering, OH
Click here to add this to my saved trials
La Jolla, California 92037
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
(305) 243-1000
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Milwaukee, Wisconsin 53211
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
8800 W. Doyne Avenue
Milwaukee, Wisconsin 53226
(414) 805-6840
Medical College of Wisconsin Cancer Center Cancer touches everyone in our community, and for many,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
701 Park Ave
Minneapolis, Minnesota 55415
(612) 873-3000
Hennepin County Medical Center - Minneapolis Hennepin Healthcare System, Inc. operates Hennepin County Medical Center...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Munster, Indiana 46321
?
mi
from
Munster, IN
Click here to add this to my saved trials
195 Little Albany St
New Brunswick, New Jersey 08903
(732) 235-2465
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School As New...
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New Orleans, Louisiana 70121
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
201 Lyons Ave
Newark, New Jersey 07112
(973) 926-7000
Newark Beth Israel Medical Center Newark Beth Israel Medical Center, a regional care, teaching hospital...
?
mi
from
Newark, NJ
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
?
mi
from
Oak Park, IL
Click here to add this to my saved trials
400 30th Street, Suite 301
Oakland, California 94609
(510) 465-8016
CCOP - Bay Area Tumor Institute he Bay Area Tumor Institute Community Clinical Oncology Program...
?
mi
from
Oakland, CA
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Parkersburg, West Virginia 26101
?
mi
from
Parkersburg, WV
Click here to add this to my saved trials
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19141
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials